A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors

NCT03184870 PHASE1, PHASE2 COMPLETED Results posted

The purpose of this study is to evaluate the safety profile, tolerability, drug levels, drug effects, and preliminary efficacy of BMS-813160 alone or in combination with either chemotherapy or nivolumab or chemotherapy plus nivolumab in participants with metastatic colorectal and pancreatic cancers.

Details

Lead sponsor	Bristol-Myers Squibb
Phase	PHASE1, PHASE2
Status	COMPLETED
Enrolment	332
Start date	Tue Aug 08 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Jun 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Colorectal Cancer
• Pancreatic Cancer

Interventions

• BMS-813160
• Nivolumab
• Nab-paclitaxel
• Gemcitabine
• 5-fluorouracil (5-FU)
• Leucovorin
• Irinotecan

Countries

Belgium, Germany, Canada, Australia, United States, Spain